Achieve Life Sciences (NASDAQ:ACHV) reported quarterly losses of $(0.83) per share which met the analyst consensus estimate. This is a 9.21 percent decrease over losses of $(0.76) per share from the same period last year.
Barclays Maintains Overweight on AZEK Co, Lowers Price Target to $23
Barclays analyst Matthew Bouley maintains AZEK Co (NYSE:AZEK) with a Overweight and lowers the price target from $27 to $23.